Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide

Diabetes Research and Clinical Practice

Volumn 93, Issue 1, 2011, Pages

  Seck, Thomas L ^a   Engel, Samuel S ^a   Williams Herman, Debora E ^a   Sisk, Christine McCrary ^a   Golm, Gregory T ^a   Wang, Hongwei ^a   Kaufman, Keith D ^a   Goldstein, Barry J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Dipeptidyl peptidase IV; Glipizide; Incretins; Sitagliptin; Sulfonylurea

Indexed keywords

GLIPIZIDE; GLYCOSYLATED HEMOGLOBIN; METFORMIN; SITAGLIPTIN;

ARTICLE; COMPARATIVE EFFECTIVENESS; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; SIDE EFFECT; TREATMENT DURATION; WEIGHT GAIN;

AGED; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; GLIPIZIDE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PYRAZINES; TRIAZOLES; WEIGHT GAIN;

EID: 79960556131     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2011.03.006     Document Type: Article

References (9)

1. Riddle M.C. Glycemic management of type 2 diabetes: an emerging strategy with oral agents, insulins, and combinations. Endocrinol Metab Clin North Am 2005, 34:77-98.
2. Inzucchi S.E. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002, 287:360-372.
3. Krentz A.J., Bailey C.J. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005, 65:385-411.
4. Herman G.A., Bergman A., Stevens C., Kotey P., Yi B., Zhao P., et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels following an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006, 91:4612-4619.
5. Kim D., Wang L., Beconi M., Eiermann G.J., Fisher M.H., He H., et al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4] triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005, 48:141-151.
6. Drucker D.J., Nauck M.A. GLP-1R agonists (incretin mimetics) and DPP-4 inhibitors (incretin enhancers) for the treatment of type 2 diabetes. Lancet 2006, 368:1696-1705.
7. Nauck M.A., Meininger G., Sheng D., Terranella L., Stein P.P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007, 9:194-205.
8. Turner R.C., Cull C.A., Fighi V., Holman R.R. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies. UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999, 281:2005-2012.
9. Nathan D.M., Buse J.B., Davidson M.B., Ferrannini E., Holman R.R., Sherwin R., et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32:193-203.